51061-22-4

Basic information

• Product Name: 3-PHENOXYPHENETHYLAMINE
• Synonyms: 3-PHENOXYPHENETHYLAMINE;3-(BENZYLOXY)PHENYLETHYLAMINE;3-(BENZYLOXY)PHENETHYLAMINE;2-(3-BENZYLOXY-PHENYL)-ETHYLAMINE;2-(3-PHENOXY-PHENYL)-ETHYLAMINE;RARECHEM AL BW 1362;RARECHEM AL BW 0361;2-(3-Benzyloxy-phenyl)-ethylamine HCl
• CAS NO: 51061-22-4
• Molecular Formula: C₁₅H₁₇NO
• Molecular Weight: 213.27
• Product Categories: pharmacetical
• Mol File: 51061-22-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 370.1°Cat760mmHg
• Flash Point: 179.3°C
• Appearance: /
• Density: 1.079g/cm³
• Vapor Pressure: 1.13E-05mmHg at 25°C
• Refractive Index: 1.584
• PKA: 9.84±0.10(Predicted)
• CAS DataBase Reference: 3-PHENOXYPHENETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PHENOXYPHENETHYLAMINE(51061-22-4)
• EPA Substance Registry System: 3-PHENOXYPHENETHYLAMINE(51061-22-4)

Safety Data

• Hazardous Substances Data: 51061-22-4(Hazardous Substances Data)

Usage

General Description

3-Phenoxyphenethylamine, also known as mescaline phenyl ether, is a chemical compound with the formula C16H17NO2. It is a phenethylamine derivative and is similar in structure to mescaline, a naturally occurring psychedelic alkaloid found in certain cacti. 3-Phenoxyphenethylamine has been shown to have psychoactive effects and is considered to be a psychoactive drug. It is known to act as a psychedelic and hallucinogenic compound, and has been used as a recreational drug. However, its effects and safety profile have not been extensively studied, and its use is generally not recommended due to potential health risks and legal concerns.

InChI:InChI=1/C15H17NO/c16-10-9-13-7-4-8-15(11-13)17-12-14-5-2-1-3-6-14/h1-8,11H,9-10,12,16H2

Upstream product

• 198884-08-1 1-benzyloxy-3-(2-nitro-ethyl)-benzene 
• 20967-96-8 2-(3-benzyloxyphenyl)acetonitrile 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 29973-97-5 2-(3-benzyloxyphenyl)ethyl amine hydrochloride 
• 14044-65-6 borane-THF 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 24550-32-1 1-(benzyloxy)-3-[(E)-2-nitroethenyl]benzene 
• 24550-32-1 1-(benzyloxy)-3-(2-nitrovinyl)benzene 

Downstream Products

• 91421-60-2 N-(3-benzyloxyphenethyl)-2-(6-bromo-3,4-dimethoxyphenyl)acetamide 
• 588-05-6 m-tyramine 
• 188662-08-0 N-[2-(3-Benzyloxy-phenyl)-ethyl]-3-(4-hydroxy-phenyl)-propionamide 
• 188662-10-4 N-[2-(3-Benzyloxy-phenyl)-ethyl]-3-(3-hydroxy-phenyl)-propionamide 
• 478855-44-6 N-[2-(3-benzyloxy-phenyl)-ethyl]-benzamide 
• 1414380-10-1 ethyl [β-(3-benzyloxy)phenethylamino]-oxobutanoate 
• 1414380-12-3 8-benzyloxy-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-3-one 
• 1414380-16-7 8-(4-fluorobenzyloxy)-1,2,3,5,6,10a-hexahydropyrrolo[2,1-a]isoquinolin-3-one 
• 1414380-17-8 C₂₀H₂₀N₂O₃ 

Relevant articles and documents

NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

A compound according to Formula (I): wherein R1, LA, CyA, RA, R2, R3, and R4 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions, pain, neuroinflammatory conditions, neurodegenerative conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, cardiovascular diseases, leukemia, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products

Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.

Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones

The attractive structure of the pyrroloisoquinoline moiety, together with its potential antimicrobial activity, encouraged us to prepare six 8-substituted and seven 8,9-disubstituted-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-3- ones in a few steps with good yields. We applied a convenient methodology via double intramolecular cyclization conducted by a Bischler-Napieralski cyclodehydration-imine reduction sequence, which is widely employed in the synthesis of isoquinoline alkaloids. Therefore, we synthesized three series of these pyrrolo[2,1-a]isoquinolin-3-ones characterized by the substituent at the 8-position or 8,9-positions of the aromatic ring: (a) different side chains are attached to an 8-OH group (series 1); (b) a chlorine atom is attached to the 8-position (series 2); and (c) 8- and 9-carbons are bearing an identical group (series 3). The compounds bearing a benzylic moiety at the 8-position, for example, 8-benzyloxy-pyrrolo[2,1-a]isoquinolin-3-one (1a) and 8-(4-fluorobenzyloxy)-pyrrolo[2,1-a]isoquinolin-3-one (1e), as well as, a 8-chloro-9-methoxy moiety including the 8-chloro-9-methoxy-pyrrolo[2,1-a] isoquinolin-3-one (2a), provided the most fungicide and bactericide agents, respectively.